Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 52 of 55
FTSE100 closes lower after strong US jobs number
The US economy added 271,000 jobs in October compared to forecasts of around 180,000
More M&A to follow AstraZeneca tie-up with ZS Pharma
Companies likely to do bolt-on deals as well as big takeovers
Investments and investor services
US job hopes boost markets in London and Asia
The FTSE 100 Index climbed four points to 6368 in early trading
AstraZeneca to buy US drug firm ZS Pharma for $2.7bn
ZS Pharma is developing a drug to treat high potassium levels in the bloodstream
Archive
FTSE100 closes lower as Anglo American tumbles
After a brief foray into the black, Footsie went lower.....
Blue-chips bounce back after Bank of England rate decision
The FTSE 100 Index pared losses to stand 1.5 points up at 6414 by lunchtime
AstraZeneca upgrade cheers despite Crestor warning
Drug group's shares rise as it forecasts flat annual revenue and higher earnings
Stocks set to claw back the bulk of yesterday's losses
Facebook is set to lead stocks higher after it revealed it had passed the 1bn mark for daily active users.
Miners and Morrisons drag down London market
The FTSE 100 Index was 27.26 points off at 6385 in morning trading
Risers and fallers, including Alliance Pharma, Thoams Cook, TUI AG and OPG Power
Here are some major share risers and fallers at 1.30pm.....
AstraZeneca ups profit guidance but sees tough 2016
The group said total annual revenue would match last year's rather than declining
Thursday's agenda: Top-line disappointment in store for Morrisons and Astra
Not much chance to catch your breath at 7.00am on Thursday, with a cavalcade of company updates scheduled.
AstraZeneca's main headaches: FX, generics and slowing Chinese growth
Currency movements and competition from cheaper generic versions of its drugs means it is most unlikely Astra will keep its growth story going
Week ahead: Marks aims to emulate Next's success
Marks reports on Wednesday, while a host of other companies report alond with a slew of economic data.
AstraZeneca's ovarian drug tests well for prostate cancer
Drug companies are looking at ways to target tumours by genetic mutation rather than where they are in the body.
AstraZeneca gout drug approval seen as mild positive
Hyperuricemia, where an excess of uric acid leads to crystals forming around the joints, causes the disease.
Investments and investor services
Shares stay red as market gives thumbs-down to Glencore
The Footsie fell 35.39 points to 6,380 as bullish sentiment disappeared
London shares fall as markets take stock
Shares in the red as traders ponder next moves ahead of busy week